Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CNCE
  • CUSIP: N/A
  • Web: www.concertpharma.com
Capitalization:
  • Market Cap: $337.58 million
  • Outstanding Shares: 22,687,000
Average Prices:
  • 50 Day Moving Avg: $14.62
  • 200 Day Moving Avg: $14.98
  • 52 Week Range: $7.11 - $19.11
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.75
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $82,000.00
  • Price / Sales: 4,147.29
  • Book Value: $2.85 per share
  • Price / Book: 5.26
Profitability:
  • EBIDTA: ($49,110,000.00)
  • Net Margins: -60,681.70%
  • Return on Equity: -61.98%
  • Return on Assets: -48.50%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 17.50%
  • Quick Ratio: 17.50%
Misc:
  • Average Volume: 124,478 shs.
  • Beta: 1.47
  • Short Ratio: 2.44
 

Frequently Asked Questions for Concert Pharmaceuticals (NASDAQ:CNCE)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.04. The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.20 million. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. View Concert Pharmaceuticals' Earnings History.

When will Concert Pharmaceuticals make its next earnings announcement?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Concert Pharmaceuticals.

Where is Concert Pharmaceuticals' stock going? Where will Concert Pharmaceuticals' stock price be in 2017?

4 analysts have issued twelve-month price objectives for Concert Pharmaceuticals' shares. Their predictions range from $20.00 to $32.00. On average, they anticipate Concert Pharmaceuticals' stock price to reach $26.75 in the next year. View Analyst Ratings for Concert Pharmaceuticals.

What are analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (9/18/2017)
  • 2. HC Wainwright analysts commented, "de-risked platform for drug discovery" along with a lead clinical asset for alopecia areata.Over the past five years, the company has leveraged its proprietary platform as a source for external partnerships and has had four validating partnership deals, the analyst continued. The most recent partnership related to the acquisition of CTP-656 which is under FTC review before the final close date in October.While there is "little clarity" into the review process of CTP-656, investors should believe in the "fundamental value of a deuterated potentiator to the many players still eager to assemble the best-in-class triple combo for cystic fibrosis," Fein stated.CTP-543The recent clinical hold lift of Concert's CTP-543, a deuterated ruxolitinib (a JAK1/2 inhibitor), for the treatment of adults with moderate-to-severe AA, should be viewed as the removal of an overhang and clears a path for a phase 2a readout in the bottom half of 2018, Fein also noted."We suspect that this clinical hold may [have] less to do with endogenous factors (e.g., the compound or trial itself), and more to do with exogenous factors (e.g., the evolving sphere of research around AA field and JAK inhibitor research broadly)," he wrote. "As such, we applaud management's attitude in starting an open and conciliatory dialogue with the agency early on to prevent any possible negative downstream scenarios and allow the data to speak for itself." (7/24/2017)
  • 3. Aegis analysts commented, "We still anticipate the deal to close and for Concert to receive the $160 mil upfront payment." (6/12/2017)

Who are some of Concert Pharmaceuticals' key competitors?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:

  • Richard H. Aldrich, Chairman of the Board, Co-Founder
  • Roger D. Tung Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Ryan Lynch, Principal Financial Officer, Principal Accounting Officer
  • Nancy Stuart, Chief Operating Officer
  • Robert Silverman Ph.D. J.D., Senior Vice President and General Counsel
  • James Cassella,, Senior Vice President, chief development officer
  • Christine Boisclair, Vice President - Regulatory Affairs
  • Scott Weintraub, Vice President - Commercial and Product Strategy
  • Thomas G. Auchincloss Jr., Director
  • Ronald W. Barrett Ph.D., Director

Who owns Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.68%), Vanguard Group Inc. (3.35%), Franklin Resources Inc. (3.04%), Citadel Advisors LLC (2.11%), Lyon Street Capital LLC (1.92%) and Senzar Asset Management LLC (1.83%). Company insiders that own Concert Pharmaceuticals stock include Nancy Stuart, Pauline Mcgowan, Roger D Tung, Ronald W Barrett, Ryan Lynch, Thomas G Auchincloss and Wilfred E Jaeger. View Institutional Ownership Trends for Concert Pharmaceuticals.

Who sold Concert Pharmaceuticals stock? Who is selling Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Virginia Retirement Systems ET AL, Goldman Sachs Group Inc., Wells Fargo & Company MN, Senzar Asset Management LLC, California State Teachers Retirement System and New York State Common Retirement Fund. View Insider Buying and Selling for Concert Pharmaceuticals.

Who bought Concert Pharmaceuticals stock? Who is buying Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Lyon Street Capital LLC, QS Investors LLC, Vanguard Group Inc., Senvest Management LLC, PNC Financial Services Group Inc., Fisher Asset Management LLC and Marshall Wace North America L.P.. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung and Thomas G Auchincloss. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy Concert Pharmaceuticals stock?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $14.99.


MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Concert Pharmaceuticals (NASDAQ:CNCE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.75 (78.45% upside)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/18/2017HC WainwrightReiterated RatingBuy$20.00LowView Rating Details
7/10/2017Stifel NicolausReiterated RatingBuy$31.00 -> $30.00HighView Rating Details
6/12/2017AegisReiterated RatingBuy$25.00LowView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00N/AView Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Earnings History by Quarter for Concert Pharmaceuticals (NASDAQ CNCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.54)N/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.58)$0.20 million$0.02 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.54)($0.60)$0.02 millionViewListenView Earnings Details
3/6/2017Q4 2016($0.66)($0.54)$0.02 millionViewListenView Earnings Details
11/8/2016Q316($0.63)($0.51)$0.06 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)$0.06 million$0.07 millionViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.66 million$0.06 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)($0.40)$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.77 million$1.31 millionViewN/AView Earnings Details
11/12/2014Q314($0.45)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.40)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
Current Year EPS Consensus Estimate: $-2.57 EPS
Next Year EPS Consensus Estimate: $-2.22 EPS

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Concert Pharmaceuticals (NASDAQ:CNCE)
Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 61.62%
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Ryan LynchInsiderSell3,500$14.51$50,785.00View SEC Filing  
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Concert Pharmaceuticals (NASDAQ:CNCE)
Latest Headlines for Concert Pharmaceuticals (NASDAQ:CNCE)
Source:
DateHeadline
americanbankingnews.com logoConcert Pharmaceuticals' (CNCE) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 18 at 10:16 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Insider Sells $50,785.00 in Stock
www.americanbankingnews.com - September 18 at 8:08 PM
americanbankingnews.com logoZacks Investment Research Upgrades Concert Pharmaceuticals, Inc. (CNCE) to "Buy"
www.americanbankingnews.com - September 18 at 5:46 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - September 15 at 6:10 PM
americanbankingnews.com logoConcert Pharmaceuticals (CNCE) & Its Competitors Financial Analysis
www.americanbankingnews.com - September 14 at 6:06 AM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 6 at 6:46 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Upgraded at ValuEngine
www.americanbankingnews.com - September 3 at 5:52 PM
finance.yahoo.com logoConcert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
finance.yahoo.com - August 31 at 5:15 PM
americanbankingnews.com logo Brokerages Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Quarterly Sales of $20,000.00
www.americanbankingnews.com - August 30 at 11:28 AM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - August 29 at 6:30 PM
americanbankingnews.com logo Analysts Anticipate Concert Pharmaceuticals, Inc. (CNCE) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - August 28 at 9:54 AM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 22, 2017
finance.yahoo.com - August 24 at 5:29 PM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:29 PM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : August 23, 2017
finance.yahoo.com - August 23 at 5:55 PM
finance.yahoo.com logoEdited Transcript of CNCE earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 13 at 9:58 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 6:56 PM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 11, 2017
finance.yahoo.com - August 11 at 5:44 PM
americanbankingnews.com logoConcert Pharmaceuticals Inc (NASDAQ:CNCE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 10 at 6:20 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:54 PM
rttnews.com logoConcert Pharma Q2 Net Loss Slightly Narrows
www.rttnews.com - August 8 at 5:02 PM
finance.yahoo.com logoConcert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - August 8 at 5:02 PM
finance.yahoo.com logoConcert reports 2Q loss
finance.yahoo.com - August 8 at 5:02 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - August 6 at 12:42 PM
finance.yahoo.com logoConcert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - August 1 at 5:59 PM
benzinga.com logoConcert Pharma Shares Rally Over $15 Level Following New Buy Rating, $20 Price Target
www.benzinga.com - July 25 at 5:18 PM
finance.yahoo.com logoVertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656
finance.yahoo.com - July 25 at 5:18 PM
finance.yahoo.com logoConcert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex
finance.yahoo.com - July 24 at 11:23 AM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Now Covered by HC Wainwright
www.americanbankingnews.com - July 24 at 9:36 AM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - July 20 at 5:21 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 18 at 6:56 PM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : July 18, 2017
finance.yahoo.com - July 18 at 6:50 PM
reuters.com logoBRIEF-Concert Pharma says FDA lifts clinical hold on its clinical trial with CTP-543
www.reuters.com - July 12 at 11:07 PM
rttnews.com logoARNA Heartened By Phase II Trial, BMY To Face FDA In Nov., Concert Back In Play
www.rttnews.com - July 11 at 11:27 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Given "Buy" Rating at Stifel Nicolaus
www.americanbankingnews.com - July 10 at 11:00 PM
streetinsider.com logoConcert Pharma (CNCE) Announces FDA Lifts Clinical Hold on Clinical Trial with CTP-543
www.streetinsider.com - July 10 at 5:20 PM
nasdaq.com logoFDA lifts hold on Concert Pharma's hair loss drug
www.nasdaq.com - July 10 at 5:20 PM
seekingalpha.com logoConcert Pharmaceuticals Provides Investment Opportunity With Deuterated Drug Technology
seekingalpha.com - July 10 at 5:20 PM
finance.yahoo.com logoFDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543
finance.yahoo.com - July 10 at 5:20 PM
finance.yahoo.com logoFDA lifts hold on Concert Pharma's study testing hair loss drug
finance.yahoo.com - July 10 at 5:20 PM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : July 7, 2017
finance.yahoo.com - July 8 at 9:54 AM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : June 26, 2017
finance.yahoo.com - June 26 at 10:10 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Expected to Announce Earnings of -$0.62 Per Share
www.americanbankingnews.com - June 26 at 2:30 PM
americanbankingnews.com logoConcert Pharmaceuticals Inc (CNCE) Upgraded at ValuEngine
www.americanbankingnews.com - June 24 at 12:38 AM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 23 at 5:06 PM
finance.yahoo.com logoConcert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : June 23, 2017
finance.yahoo.com - June 23 at 4:59 PM
finance.yahoo.com logoConcert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital
finance.yahoo.com - June 12 at 5:24 PM
americanbankingnews.com logoConcert Pharmaceuticals, Inc. (CNCE) Receives Buy Rating from Aegis
www.americanbankingnews.com - June 12 at 1:48 PM
seekingalpha.com logoConcert Pharmaceuticals (CNCE) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 7:47 PM
americanbankingnews.com logo Analysts Expect Concert Pharmaceuticals Inc (CNCE) Will Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - May 31 at 10:32 AM
finance.yahoo.com logoConcert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws
finance.yahoo.com - May 30 at 11:59 AM

Social

Chart

Concert Pharmaceuticals (CNCE) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff